Less than 5 years ago, it was still not clear whether anti-angiogenic drugs would prove successful in the clinic. After numerous patients with cancer or age-related macular degeneration have been treated with these drugs, they have now become part of the standard range of therapeutic tools. Despite this milestone, anti-angiogenic therapy still faces a number of clinical hurdles, such as improving efficacy, avoiding escape and resistance, and minimizing toxicity. Hopefully, other agents with complementary mechanisms, such as those that target placental growth factor, will offer novel opportunities for improved treatment. © 2008 Macmillan Publishers Limited. All rights reserved.

FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy?

Mazzone M.;
2008-01-01

Abstract

Less than 5 years ago, it was still not clear whether anti-angiogenic drugs would prove successful in the clinic. After numerous patients with cancer or age-related macular degeneration have been treated with these drugs, they have now become part of the standard range of therapeutic tools. Despite this milestone, anti-angiogenic therapy still faces a number of clinical hurdles, such as improving efficacy, avoiding escape and resistance, and minimizing toxicity. Hopefully, other agents with complementary mechanisms, such as those that target placental growth factor, will offer novel opportunities for improved treatment. © 2008 Macmillan Publishers Limited. All rights reserved.
2008
Angiogenesis Inhibitors
Glycosylphosphatidylinositols
Humans
Macular Degeneration
Membrane Proteins
Neoplasms
Neovascularization
Pathologic
Placenta Growth Factor
Pregnancy Proteins
Receptors
Vascular Endothelial Growth Factor
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor B
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-2
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/83142
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 500
  • ???jsp.display-item.citation.isi??? 473
social impact